



Original Article

Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin

Amelia L. Quinn,^{1,2} Olivia M. Dean,^{3,4,5,6} Christopher G. Davey,^{1,2,7} Melissa Kerr,^{1,2} Susy M. Harrigan,^{1,2} Sue M. Cotton,^{1,2} Andrew M. Chanen,^{1,2,7} Seetal Dodd,^{3,5,6} Aswin Ratheesh,^{1,2,7} G. Paul Amminger,^{1,2} Mark Phelan,^{1,2,7} Amber Williams,^{1,2} Andrew Mackinnon,^{1,2} Francesco Giorlando,^{5,7} Shelley Baird,^{1,2} Simon Rice,^{1,2,7} Melissa O'Shea,⁶ Miriam R. Schäfer,^{1,2} Edward Mullen,^{1,2,7} Sarah Hetrick,^{1,2} Patrick McGorry,^{1,2} and Michael Berk^{1,2,3,4,5,6}

Abstract

Aim: There is growing support for the role of inflammation and oxidative stress in the pathophysiology of major depressive disorder (MDD). This has led to the development of novel strategies targeting inflammation in the treatment of depression. Rosuvastatin and aspirin have well-documented, anti-inflammatory and antioxidant properties. The aim of the Youth Depression Alleviation: Augmentation with an anti-inflammatory agent (YoDA-A) study is to determine whether individuals receiving adjunctive anti-inflammatory agents, aspirin and rosuvastatin experience a reduction in the severity of MDD compared with individuals receiving placebo.

Methods: YoDA-A is a 12-week triple-blind, randomized controlled trial funded by the National Health and Medical Research Council, Australia. Participants aged 15–25, with moderate-to-severe MDD, are allocated to receive either 10 mg/day

rosuvastatin, 100 mg/day aspirin, or placebo, in addition to treatment as usual. Participants are assessed at baseline and at weeks 4, 8, 12 and 26. The primary outcome is change in the Montgomery–Åsberg Depression Rating Scale (MADRS) from baseline to week 12.

Results: The study is planned to be completed in 2017. At date of publication, 85 participants have been recruited.

Conclusion: Timely and targeted intervention for youth MDD is crucial. Given the paucity of new agents to treat youth MDD, adjunctive trials are not only pragmatic and 'real-world', but additionally aim to target shortfalls in conventional medications. This study has the potential to first provide two new adjunctive treatment options for youth MDD; aspirin and rosuvastatin. Second, this study will serve as proof of principle of the role of inflammation in MDD.

¹Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia, ²Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia, ³Deakin University, IMPACT Strategic Research Centre, School of Medicine, ⁴Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, ⁵Department of Psychiatry, University of Melbourne, Parkville, Australia, ⁶Barwon Health, Geelong, Australia, ⁷Orygen Youth Health, Northwestern Mental Health, Melbourne, Australia

Corresponding author: Ms Amelia L. Quinn, Orygen, the National Centre of Excellence in Youth Mental Health, Locked Bag 10, Parkville, Vic. 3052, Australia. Email: amelia.lopatecki@orygen.org.au

Received 3 August 2015; accepted 9 September 2015

Key words: aspirin, depression, inflammation, rosuvastatin, youth.

Disclosures

ALQ has no disclosures to report. OMD is a Research Fellow and has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Australian Rotary Health, Stanley Medical Research Institute, Deakin University, Brazilian Society Mobility Program Lilly, National Health and Medical Research Council of Australia (NHMRC) and an ASBD/Servier grant. She has also received in-kind support from BioMedica Nutraceuticals, NutritionCare and Bioceticals. MK has no disclosures to report. SMH has received support from Eli Lilly. SMC has no disclosures to report. AC has no disclosures to report. SD has received grant and/or research support from the Stanley Medical Research Institute, NHMRC, Beyond Blue, ARHRF, Simons Foundation, Geelong Medical Research Foundation, Fondation FondaMental, Eli Lilly, Glaxo SmithKline, Organon, Mayne Pharma, Servier. He has received speaker's fees from Eli Lilly, advisory board fees from Eli Lilly and Novartis and conference travel support from Servier. AR has no disclosures to report. FG has received grant/research support from the Australasian Society for Bipolar & Depressive Disorders (ASBDD/AstraZeneca Scholarship), Pfizer and the RANZCP (Royal Australian and New Zealand College of Psychiatrists). SH was an NHMRC Training Fellow at time of trial funding. MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bioadvantex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and Servier.

INTRODUCTION

Depression is the most prevalent health problem in young people, with up to 24% experiencing major depressive disorder (MDD) before they reach the age of 25.¹ These rates may be increasing.² MDD in youth is of particular concern, not only due to the social and developmental impact of the disease^{3,4} but also because depression during this period may lead to multiple recurrent major depressive episodes.^{5,6}

Depression theories and treatments have focused on the monoamine hypothesis, postulating that depression is the result of a deficiency of certain monoamine neurotransmitters.⁷ Although monoamines play a role in depression, this approach has neither delivered effective treatments for many individuals, nor produced novel agents, beyond the limited treatment options currently available.^{8,9} Current conceptualization of the neurobiology of depression has shifted from monoamines, incorporating changes in inflammatory and oxidative stress into a more comprehensive model of illness neuroprogression.¹⁰

Stress and depression are associated with increased immune activation, impaired immune function and inflammation.^{11,12} Adolescent depression is associated with an inflammatory response.¹³ Elevated levels of C-reactive protein (CRP; a marker of inflammation) predict the later onset of depression, suggesting that the immune findings contribute to the genesis of the disorder.¹⁴ Some antidepressant treatments reduce inflammatory marker levels in MDD patients^{15,16} and reduce the release of inflammatory factors from stimulated microglia.^{17,18} Lack of treatment response to traditional antidepressants is associated with elevated inflammatory marker levels,^{19,20} suggesting an

immunomodulatory role for successful use of antidepressant medication and opening the door to interventions that directly target the pathophysiology of depression.

The relationship between oxidative stress and depression is also supported. Compared with healthy controls, individuals experiencing a major depressive episode have significantly elevated markers of oxidative damage,²¹ while oxidative stress is significantly higher in medication-free patients with MDD than in controls.²² Positive correlations have been shown between oxidative stress index values and depressive severity scores.^{22–26} Oxidative parameters return to normal with the resolution of depressive symptoms after selective serotonin re-uptake inhibitor treatment, supporting the contention that oxidative stress has an intrinsic role in the disease process.^{23,27}

There is currently minimal evidence to support the effectiveness of any non-psychotherapeutic treatment for depression in young people, with the exception of fluoxetine.^{28,29} Although effective, fluoxetine carries an increased risk of suicidal ideation in those aged under 25.^{30–33} There is, therefore, a clear need for the development of interventions with demonstrated effectiveness, which are acceptable to young people experiencing MDD. Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), such as rosuvastatin (a hydrophilic statin) and lovastatin (a lipophilic statin), have well-documented anti-inflammatory and antioxidant properties, as do aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs).^{34,35}

In vivo statin treatment has been demonstrated to reduce oxidative stress.^{36–39} Rosuvastatin reduced markers of oxidative stress and inflammation in animals³⁴ and in patients with hypertension and dyslipidaemia.³⁵ In an adult sample, lovastatin,

when used as adjunctive treatment, was effective for treating patients with MDD.⁴⁰ Based on its action in reducing oxidative stress and the association of oxidative stress and depressive symptoms, rosuvastatin may be useful in reducing symptoms.

Adults with first-episode depression receiving aspirin together with fluoxetine had a greater reduction of oxidative stress than those receiving fluoxetine monotherapy.⁴¹ A recent study has shown that aspirin reduces core symptoms of schizophrenia, with a significant decrease in total and positive symptoms.⁴² Given the biological similarities between mood and psychotic disorders, this is an intriguing lead.

The above evidence supports a possible role of oxidative and inflammatory processes in depression. It argues for the evaluation of rational and novel pathophysiologically based therapies that are distinct from conventional antidepressants.

METHODS

Study design

The study design is a 12-week parallel group, triple-blind, randomized controlled trial in participants with moderate-to-severe MDD, allocated to receive either rosuvastatin, aspirin or placebo, in addition to treatment as usual (TAU). Assessments are completed at baseline and at weeks 4, 8 and 12, with a telephone follow-up assessment at week 26 to determine post-discontinuation effects. Blood samples are collected at baseline and at week 12 for the investigation of inflammatory and oxidative stress markers. The most relevant markers, based on current literature at the end of the study, will be explored. The study was approved by the Melbourne Health Human Research Ethics Committee (#HREC/12/MH/148). The study was funded by the National Health and Medical Research Council of Australia and sponsored by Orygen, the National Centre of Excellence in Youth Mental Health, without limitations on publication.

The primary hypothesis is that after 12 weeks of treatment, both the rosuvastatin and aspirin treatment groups will show greater improvement from baseline than the placebo group on the Montgomery-Åsberg Depression Rating Scale (MADRS).⁴³

The secondary hypotheses are that the rosuvastatin and aspirin treatment groups will show greater improvement compared with the placebo group on measures of clinical global status, functioning, quality of life and symptomatology from baseline to week 12; that these effects, and the

reduction in MADRS, will be seen at week 26 follow up in the rosuvastatin and aspirin groups, compared with placebo; and that those in the active arms will have reduced levels of inflammatory and oxidative stress levels in serum; and that oxidative stress and inflammation will mediate clinical change.

Tertiary analyses will also be completed to explore mediating factors in the response to rosuvastatin and aspirin treatment.

Study setting

The study is being conducted at the Youth Mood Clinic at Orygen Youth Health (OYH), Jigsaw – Barwon Health, and in *headspace* centres in Geelong and Melbourne, Australia.

TAU at these sites includes case management, cognitive behavioural therapy and pharmacotherapy.

The study commenced recruitment in June 2013 at OYH and *headspace* centres at Glenroy and Sunshine, Victoria. Recruitment at Barwon Health site and Geelong *headspace* will commence in coming months. The study has recruited 85 participants to date and of those, 54 have completed week 12 and 33 have completed week 26.

Inclusion and exclusion criteria

To be included in the study, participants must: (i) be aged between 15 and 25 years; (ii) have a diagnosis of current MDD using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient version (SCID-I/P)⁴⁴; (iii) have a score on the MADRS⁴³ of 20 or greater, indicating moderate-to-severe depression; (iv) have the ability to give informed consent and to comply with standard procedures; (v) use effective contraception if female and sexually active with members of the opposite sex; (vi) have fluency in English; and (vii) have stable pharmacological treatment for at least 2 weeks prior to enrolment (any changes in medication dose or frequency of therapy are excepted), if currently being treated.

Exclusion criteria are: (i) lifetime or current SCID-I/P diagnosis of a psychotic disorder; (ii) a lifetime SCID-I/P diagnosis of bipolar I or II disorder or alcohol dependence; (iii) an acute or unstable systemic medical disorder; (iv) an inability to comply with the requirements of informed consent or the study protocol; (v) a history of intolerance or allergy to study medications; (vi) those who are currently pregnant or breast-feeding; (vii) the current regular use of statins, aspirin, NSAID's paracetamol, corticosteroids or any other immunomodulatory

agents; and (viii) the current or recent use of hypolipidaemics, vitamin K antagonists and other anticoagulants, protease inhibitors, ketoconazole, spironolactone or cimetidine.

Discontinuation and withdrawal

Discontinuation of a participant occurs at the discretion of the participant, researcher or treating physician. Automatic discontinuation occurs if a participant develops a psychotic disorder, bipolar disorder (BD), is pregnant or at risk of pregnancy, or if he/she commences rosuvastatin or aspirin treatment. Because of the increased risk of myopathy with rosuvastatin and concurrent heavy alcohol use, a score >20 on the Alcohol Use Disorders Identification Test (AUDIT)⁴⁵ necessitates review by the treating physician, and potential discontinuation. Because of the increased risk of bleeding with aspirin, any surgery planned by the participant requires review by the treating physician. Upon discontinuation, the participant is offered the opportunity to continue to contribute to data collection at the follow-up time points.

Interventions

Participants receive either 10 mg/day rosuvastatin or 100 mg/day aspirin, or placebo, in addition to TAU. At each visit, participants are requested to return all unused investigational products. Adherence to medication is assessed by a pill count.

The doses of rosuvastatin and aspirin are derived from the literature regarding the doses at which their targeted actions are effective and the safety profile of each agent. With these factors in mind, 10 mg of rosuvastatin reflects the lowest prescribed therapeutic dose.⁴⁶ The 100 mg dose of aspirin is the same dose used to prevent cardiac events and has been shown to have anti-inflammatory properties.⁴⁶ Blinding is maintained by ensuring that the packaging and appearance of rosuvastatin, aspirin and placebo capsules are identical. All tablets are over-encapsulated for blinding purposes to appear and taste identical.

Outcome measures

The primary outcome measure is the MADRS.⁴³ The following measures are used to assess effectiveness: change in MADRS; change in the Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR)⁴⁷; change of rates of remission (defined as MADRS ≤ 7); changes in the Generalized Anxiety Disorder 7-item scale (GAD-7)⁴⁸ scores; response,

defined as the Clinical Global Impression-Severity scale and the Clinical Global Impression-Improvement scale⁴⁹; and change in self-rated depressive symptoms, assessed using the Patient Global Impression Improvement (PGI).⁵⁰ Quality of life is assessed using the Quality of life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)⁵¹ and the Social Adjustment Scale-Self Report (SAS-SR)⁵²; the Social and Occupational Functioning Scale (SOFAS)⁵³ is used to measure psychosocial (social and occupational) functioning.

Predictors, moderators and mediators of treatment response

Potential predictors and moderators of treatment response are assessed using the Dimensional Assessment of Personality Pathology-Basic Questionnaire (DAPP),⁵⁴ the SCID-I/P substance use module,⁴⁴ the AUDIT⁴⁵ and the Negative Problem Orientation Questionnaire (NPOQ).⁵⁵ Although participants with syndromal BD are excluded from the study, subthreshold bipolar symptoms are characterized in an index which includes the Bipolar Spectrum Diagnostic Scale (BSDS)⁵⁶ and the Young Mania Rating Scale (YMRS).⁵⁷ Full details of the index and outcomes will be published as a separate sub-study.

Peripheral markers of inflammation and oxidative stress will be explored in consenting participants (blood sampling is optional). Serum, plasma and whole blood are collected from 30 mL of blood, taken at baseline and at week 12. Samples are stored at -80 °C until analysis.

Participants may also optionally consent to baseline brain imaging. These data will be analysed to determine whether brain imaging variables predict treatment outcome. As this is a sub-study of the main trial, details of this protocol will be published elsewhere.

Safety and adverse events

The trial is monitored by an independent Data and Safety Monitoring Committee (DSMC). Adverse events (AEs) are collected from the time that informed consent has been obtained until the end of the week 12 intervention period using open questions. After the 12-week intervention period, AEs are followed up until the AE is resolved or until 7 days after trial medication has ceased. All serious AEs are reported to all relevant regulatory authorities.

Suicidal thinking is assessed with the Suicidal Ideation Questionnaire (SIQ)⁵⁸ and suicidality is assessed with the Columbia Suicide Severity Rating

Scale (C-SSRS).⁵⁹ If a participant scores 5 on intensity of suicidal ideation in the past month, the participant's continuation in the study is reviewed. If a participant scores 20 or above on the AUDIT at any trial visit, their treating physician is informed and the participant is reviewed.


At baseline and at week 12, specific blood tests are performed for safety purposes. At baseline, these comprise: a full blood examination, liver function tests (LFT), urea and electrolytes (U&E), CRP random glucose, vitamin B12 and folate, creatinine

kinase (CK), and thyroid stimulating hormone. At week 12, the LFT, U&E and CK are repeated.

Procedure

Written informed consent is obtained by the investigator or research assistant. If a participant is <18 years, consent is obtained from both the parent/legal guardian and the participant. If eligibility is confirmed, the baseline assessment is conducted (see Fig. 1 for participant flow chart). The partici-

FIGURE 1. Flow chart of study design.



participant is randomized to the rosuvastatin, aspirin or placebo groups. Investigators, clinicians, research assistants and statisticians are blind to treatment allocation for data collection and analysis.

Following baseline assessment and randomization, participants are subsequently assessed at weeks 4, 8 and 12 on psychopathology, functioning, AEs and side effects. Instruments and procedures implemented at each study visit are outlined in Table 1. A follow-up assessment is also conducted over the telephone at week 26. For engagement and safety purposes, the participant is also telephoned at week 2. Formal interrater reliability assessments are carried out at various stages throughout the study.

Participants are reviewed by a treating doctor at baseline, and are seen again 1 week after commencing medication. The doctor then reviews the participant at weeks 4, 8 and 12.

Randomization

Participants are randomized to the three groups in a 1:1:1 ratio. Randomization is enabled by computer-generated numbers programmed into the electronic case report form and conducted according to the International Conference on Harmonisation Guideline. The randomization is stratified by gender and age (<18 vs. ≥18 years) and participants are allocated to treatment groups using randomly permuted blocks of varying size within each stratum.

Online unblinding is available for emergency situations. If unblinded, participants discontinue treatment in the study but continue to be assessed at the scheduled times, provided they have not withdrawn consent.

Statistical analyses

Primary analyses will be undertaken on an intent-to-treat basis, including all participants as randomized, regardless of treatment actually received or withdrawal from the study. Mixed-model repeated measures (MMRM) analyses will be used to analyse change in the primary outcome measure (MADRS).⁶⁰ A priori planned comparisons of change from baseline to the week 12 end-point will be used to test the primary hypotheses. The most suitable, parsimonious variance-covariance structure for the relationships between observations at different occasions will be determined using information measures. Stratification variables and other variables found to be substantially imbalanced between groups post randomization will be tentatively included in these models and

retain if statistically significant and influential on outcomes. Similar analyses of scaled secondary measures will assess differential change on clinical global status, symptom burden, quality of life and functioning. Mathematical transformation or categorization of raw scores may be undertaken to meet distributional assumptions and address any violation of assumptions attributable to outliers. For dichotomous outcomes such as remission, a comparable mixed modelling approach will be used. Relative and reduction in risk of remission based on MADRS score status will be estimated at the trial end-point and follow up. The number needed to treat⁶¹ will be derived from these values.

In addition to intention to treat estimates of the effectiveness of each treatment, alternative estimates of effects will be calculated using subgroups identified as having complied with treatment schedules to an extent judged necessary to induce clinical change. Complier, per protocol and complier average causal effect⁶² estimates, may be examined.

The differential effectiveness of aspirin and rosuvastatin will be examined on outcome variables. As differences between the two active treatments are likely to be small, it is acknowledged that these analyses are exploratory. Safety data will be compared between treatment arms using Fisher's exact test. All tests of treatment effects will be conducted using a two-sided alpha level of 0.05% and 95% confidence intervals. Changes in biological markers will be explored between baseline and end-point and the role of oxidative stress and inflammatory markers as potential mediators of depressive symptom outcome will be investigated using structural equation models.⁶³

Determination of sample size

Based on previous work,⁴² we estimate baseline-endpoint effect sizes for the aspirin treatment to be between 0.26 and 0.47 standard deviations. Larger effect sizes for statins have been observed in epidemiological studies, with data indicating a 79% reduction in risk of developing depression.⁶⁴ An effect size of this magnitude is unlikely to be observed in a treatment study. Power calculations for the primary outcome were conservatively based on those smaller estimated effect sizes for aspirin. To sufficiently power the study (80% power) to detect differences in change from baseline of approximately 0.4 standard deviations in a priori contrasts of treatment arms conducted within the framework of omnibus test of condition-by-time MMRM analysis, and assuming a correlation of 0.5 between baseline and end-point measurements, a total sample size of 200 is required.

TABLE 1. Instruments and procedures that are implemented at each study visit

Visit	0	1	2	3	4	5	6
Week	Screening phase -3 (weeks)	Baseline 0	Phone call 2	Interim assessment 4	Interim assessment 8	Primary end-point 12	Follow-up phone interview 26
Screening and consent							
Informed consent	X	-	-	-	-	-	-
Inclusion/exclusion criteria	X	-	-	-	-	-	-
Medical history	X	-	-	-	-	-	-
Clinical blood test	X	-	-	-	-	X	-
Pregnancy test (women only)†	X	-	-	-	-	-	-
SCID-I/P	X	-	-	-	-	-	X‡
YMRS	X	-	-	-	-	X	-
Drug dispensation	-	X	-	X	X	-	-
Safety							
Adverse events recording sheet	-	-	X	X	X	X	X
SIQ	-	X	-	X	X	X	-
AUDIT	-	X	-	X	X	X	-
Effectiveness							
MADRS	-	X	-	X	X	X	X
QIDS-SR	-	X	-	X	X	X	-
GAD-7	-	X	-	X	X	X	-
CGI-S	-	X	-	X	X	X	-
CGI-I	-	-	-	X	X	X	-
PGI	-	-	-	-	-	X	-
Functioning and quality of life							
Q-LES-Q-SF	-	X	-	-	-	X	-
SOFAS	-	X	-	-	-	X	X
SAS-SR-64	-	X	-	-	-	X	-
Assessment of predictors, moderators and mediators							
DAPP-BQ	-	-	-	X	-	-	-
NPOQ	-	X	-	-	-	X	-
BSDS	-	-	-	X	-	-	-
Bipolarity index	-	-	-	X	-	-	-
Affective disorders evaluation	-	-	-	X	-	-	-
Family history questionnaire	-	-	-	-	X	-	-
Antidepressant associated mood changes	-	-	-	-	-	X	-
Subthreshold mania questions	-	X	-	-	-	-	-
Other							
Demographics	-	X	-	-	-	-	-
Psychiatric and family history	-	X	-	-	X	-	-
Concomitant medication	-	X	-	X	X	X	X
Research blood sample – biomarkers	-	X	-	-	-	X	-

†If participant is not sexually active or the treating clinician feels it is not warranted, this is not compulsory.

‡Only the mood modules from the SCID are conducted at week 26 as part of the bipolarity index.

AUDIT, Alcohol Use Disorders Identification Test; BSDS, Bipolar Spectrum Diagnostic Scale; CGI-I, Clinical Global Impression-Improvement scale; CGI-S, Clinical Global Impression-Severity scale; DAPP-BQ, Dimensional Assessment of Personality Pathology-Basic Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale; MADRS, Montgomery-Åsberg Depression Rating Scale; NPOQ, Negative Problem Orientation Questionnaire; PGI, Patient Global Impression Improvement; QIDS-SR, Quick Inventory of Depressive Symptomatology; Q-LES-Q-SF, Quality of life Enjoyment and Satisfaction Questionnaire-Short Form; SAS-SR-64, Social Adjustment Scale-Self Report; SCID-I/P, Structured Clinical Interview for DSM-IV Axis I Disorders; SIQ, Suicidal Ideation Questionnaire; SOFAS, Social and Occupational Functioning Scale; YMRS, Young Mania Rating Scale.

A sample of 270 is therefore proposed, allowing attrition rates up to 25%.

Data management

Data collection and entry is conducted according to Good Clinical Practice guidelines.^{65,66} Monitoring of the data is conducted by the DSMC, the Project Manager and the Sponsor-appointed Clinical Research Associate.

RESULTS

The study is planned to be completed in 2017. At date of publication, 85 participants have been recruited. 54 participants have completed week 12, and 33 have completed week 26.

DISCUSSION

Despite the high burden of youth depression, there is limited evidence supporting current pharmacological and psychosocial treatments in this area, leading to a call for new treatments to be developed. The current trial aims to investigate the effectiveness of add-on doses of aspirin or rosuvastatin in the treatment of youth depression.

If the study shows effectiveness in either of the two treatment arms, a novel approach to treating youth depression will be supported. Additionally, should the study demonstrate positive findings, targeted treatments might be further developed by linking the positive results seen in clinical symptoms with biological markers. This study will additionally provide information regarding the biological underpinnings of youth depression. As samples are taken at baseline and at the end of the treatment phase, this allows us to explore the pathophysiology of depression in this cohort.

Participant characteristics might moderate or mediate treatment response. Smoking, for example, has a differential effect on anti-oxidant systems among persons with bipolar and unipolar affective disorders,⁶⁷ indicating a variable impact of anti-inflammatory agents. Personality factors have been associated with both poor outcomes among depressed persons.⁶⁸ Diagnostic conversion from MDD to BD can also be examined within this study in the 6-month prospective follow up of participants included in the trial. Given the association between lower age of onset of MDD and higher risk of conversion to BD,^{69–71} the rate of conversion to BD may be moderate to high.

This study will explore the effectiveness of aspirin and rosuvastatin as novel therapies and provide meaningful data related to youth depression and the trajectory of illness in this cohort.

ACKNOWLEDGEMENTS

The study is supported by a National Health and Medical Research Project Grant and the Investigators are grateful for this support. We would also like to gratefully acknowledge the contributions of Rachel Brodie, Danijela Piskulic, Toni Scaffidi, Natalie Ferguson, Suzanne Wiltink, Lisa Incerti, Alexandra Parker, and Ben Harrison. We would also like to acknowledge the service providers and their staff including Orygen, The National Centre of Excellence in Youth Mental Health, the relevant Headspace sites and Barwon Health. CGD is funded by an NHMRC Clinical Career Development Fellowship (APP1061757). MB is supported by a NHMRC Senior Principal Research Fellowship (1059660). SR is supported by an Early Career Fellowship from the Society of Mental Health Research.

REFERENCES

1. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. *Clin Psychol Rev* 1998; **18**: 765–94.
2. Twenge JM, Gentile B, DeWall CN, Ma D, Laceyfield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: a cross-temporal meta-analysis of the MMPI. *Clin Psychol Rev* 2010; **30**: 145–54.
3. Weissman MM, Wolk S, Goldstein RB *et al*. Depressed adolescents grown up. *J Am Med Assoc* 1999; **281**: 1707–13.
4. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. *Arch Gen Psychiatry* 2002; **59**: 225–31.
5. Birmaher B, Williamson DE, Dahl RE *et al*. Clinical presentation and course of depression in youth: does onset in childhood differ from onset in adolescence? *J Am Acad Child Adolesc Psychiatry* 2004; **43**: 64–70.
6. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M. The Maudsley long-term follow-up of child and adolescent depression: 1. Psychiatric outcomes in adulthood. *Br J Psychiatry*. 2001; **179**: 210–7.
7. Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. *J Clin Psychiatry*. 2000; **61** (Suppl. 6): 4–6.
8. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression – a central role for the serotonin transporter? *Pharmacol Ther* 2015; **147**: 1–11.
9. Trivedi M, Rush AJ, Wisniewski AA *et al*. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry* 2006; **163**: 28–40.
10. Berk M, Kapczynski F, Andreazza AC *et al*. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci Biobehav Rev* 2011; **35**: 804–17.

11. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. *Brain Res* 1995; **674**: 82–90.
12. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. *J Affect Disord* 2013; **150**: 736–44.
13. Gabbay V, Klein RG, Guttman LE et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. *J Child Adolesc Psychopharmacol* 2009; **19**: 423–30.
14. Pasco JA, Nicholson GC, Williams LJ et al. Association of high-sensitivity C-reactive protein with de novo major depression. *Br J Psychiatry* 2010; **197**: 372–7.
15. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. *Neuropsychopharmacology* 2008; **33**: 166–80.
16. Basterzi AD, Aydemir C, Kisa C et al. IL-6 levels decrease with SSRI treatment in patients with major depression. *Hum Psychopharmacol* 2005; **20**: 473–6.
17. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun* 2012; **26**: 469–79.
18. Dhimi KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and citalopram decrease microglial release of glutamate and d-serine to promote cortical neuronal viability following ischemic insult. *Mol Cell Neurosci*. 2013; **56**: 365–74.
19. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; **32**: 445–50.
20. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatr Res* 2007; **41**: 326–31.
21. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. *Int J Neuropsychopharmacol* 2008; **11**: 851–76.
22. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. *Acta Neuropsychiatr*. 2004; **16**: 200–3.
23. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. *J Affect Disord* 2001; **64**: 43–51.
24. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansver E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. *Hum Psychopharmacol* 2007; **22**: 67–73.
25. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. *Psychosom Med* 2006; **68**: 1–7.
26. Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC. Low plasma vitamin E levels in major depression: diet or disease? *Eur J Clin Nutr* 2005; **59**: 304–6.
27. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. *Redox Rep* 2003; **8**: 365–70.
28. Homsy S, Federico F, Croci N et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. *Brain Res* 2009; **1291**: 122–32.
29. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *Lancet* 2004; **363**: 1341–5.
30. Laughren T Memorandum: overview for the December 13 meeting of Psychopharmacologic Drugs Advisory Committee. 2006.
31. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst Rev* 2012; (11): CD004851.
32. US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. 2004.
33. ADRAC. Use of SSRI antidepressants in children and adolescents. 2004.
34. Sicard P, Delemasure S, Korandji C et al. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. *Free Radic Res* 2008; **42**: 226–36.
35. Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. *Rev Esp Cardiol* 2007; **60**: 1242–9.
36. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. *Atherosclerosis* 2008; **199**: 278–87.
37. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. *Verh K Acad Geneesk Belg* 2008; **70**: 193–219.
38. Habibi J, Whaley-Connell A, Qazi MA et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. *Endocrinology* 2007; **148**: 2181–8.
39. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. *Clin Exp Pharmacol Physiol* 2008; **35**: 625–9.
40. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. *Depress Anxiety* 2013; **30**: 1084–8.
41. Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. *Hum Psychopharmacol* 2009; **24**: 277–86.
42. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2010; **71**: 520–7.
43. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; **134**: 382–9.
44. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), 1997.
45. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. *The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for Use in Primary Care*. Geneva: World Health Organization, 2001.
46. Australian Medicines Handbook. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2015 [cited 4 Apr 2015]. Available from URL: <https://amhonline.amh.net.au/auth>. Australian Medicines Handbook Online.
47. Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry* 2003; **54**: 573–83.

48. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing Generalized Anxiety Disorder. *Arch Intern Med* 2006; **166**: 1092–7.
49. Guy W, ed. *Clinical Global Impressions (CGI): ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.
50. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. *Am J Obstet Gynecol* 2003; **189**: 98–101.
51. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. *Psychopharmacol Bull* 1993; **29**: 321–6.
52. Weissman MM, Prusoff BA, Thompson WD, Harding PS, Myers JK. Social adjustment by self-report in a community sample and in psychiatric outpatients. *J Nerv Ment Dis* 1978; **166**: 317–26.
53. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000; **101**: 323–9.
54. Livesley WJ, Jackson DN. *Dimensional Assessment of Personality Pathology – Basic Questionnaire*. Port Huron: SIGMA Assessment Systems, 2009.
55. Robichaud M, Dugas MJ. Negative problem orientation (Part I): psychometric properties of a new measure. *Behav Res Ther* 2004; **43**: 391–401.
56. Ghaemi SN, Miller CJ, Berv DA, Klugman J, Rosenquist KJ, Pies RW. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. *J Affect Disord* 2005; **84**: 273–7.
57. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 1978; **133**: 429–35.
58. Reynolds WM. *Suicidal Ideation Questionnaire: Professional Manual*. Odessa, FL: Psychological Assessment Resources, 1988.
59. Posner K, Brown GK, Stanley B *et al*. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011; **168**: 1266–77.
60. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. *Am J Psychiatry* 2009; **166**: 639–41.
61. Altman DG. Confidence intervals for the number needed to treat. *BMJ* 1998; **317**: 1309–12.
62. Jo B, Ginexi E, Ialongo N. Handling missing data in randomized experiments with noncompliance. *Prev Sci* 2010; **11**: 384–96.
63. MacKinnon DP. *Introduction to Statistical Mediation Analysis*. New York: Erlbaum, 2008.
64. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? *J Clin Psychiatry* 2011; **72**: 1229–35.
65. Therapeutic Goods Administration. Note for guidance on good clinical practice (CPMP/ICH/135/95 – Annotated with TGA comments); 2000. [Cited 14/07/15.] Available from URL: <https://www.tga.gov.au/sites/default/files/ich13595an.pdf>
66. National Health and Medical Research Council. The national statement on ethical conduct in human research 2007 (Updated May 2015); 2015. [Cited 14/07/2015.] Available from URL: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72_national_statement_may_2015_150514_a.pdf
67. Bortolasci CC, Vargas HO, Souza-Nogueira A *et al*. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. *J Affect Disord* 2014; **159**: 23–30.
68. Newton-Howes G, Tyrer P, Johnson T *et al*. Influence of personality on the outcome of treatment in depression: a systematic review and meta-analysis. *J Pers Disord* 2014; **28**: 577–93.
69. Akiskal H, Walker FR, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. *J Affect Disord* 1983; **5**: 115–28.
70. Beesdo K, Höfler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. *Bipolar Disord* 2009; **11**: 637–49.
71. Fiederowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. *Am J Psychiatry* 2011; **168**: 40–8.